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Objectives. The present study sought to evaluate the effects of
the afterload-reducing drugs captopril and prazosin on changes in
antioxidants as well as oxidative stress in relation to hemody-
namic function in congestive heart failure (CHF) subsequent to
myocardial infarction (MI).
Background. Afterload reduction therapy has been shown to
reduce morbidity and mortality in patients with MI. CHF subse-
quent to MI in rats is associated with a decrease in myocardial
endogenous antioxidants and an increase in oxidative stress.
Methods. The left anterior descending coronary artery in male
Sprague-Dawley rats was ligated. Sham and experimental (post-
MI [PMI]) animals were assessed for hemodynamic function as
well as lung and liver weights at 1, 4 and 16 weeks after operation.
At 4 weeks, some rats were also treated with captopril (2 g/liter in
drinking water daily) or prazosin (0.2 mg/kg body weight subcu-
taneously daily) and assessed at 16 weeks. Hearts were isolated to
study the activity of superoxide dismutase (SOD), glutathione
peroxidase (GSHPx) and catalase as well as for thiobarbituric
acid reactive substances (TBARS).
Results. CHF at 4 and 16 weeks in the infarcted rats was
indicated by an increase in left ventricular end-diastolic pressure
and wet/dry weight lung and liver ratios and depressed left
ventricular systolic pressure and dyspnea. All these changes were
attenuated in both the captopril- and prazosin-treated groups.
SOD, GSHPx and catalase activity in the untreated PMI groups
was decreased at 4 and 16 weeks. However, treatment with
captopril resulted in a significant improvement in SOD, GSHPx
and catalase activity in the 16-week PMI group. With prazosin,
only SOD activity was improved in the treated 16-week PMI
group. Lipid peroxidation as indicated by TBARS was signifi-
cantly increased in the 16-week PMI group, and both captopril
and prazosin modulated this increase.
Conclusions. Occurrence of an antioxidant deficit and an in-
crease in oxidative stress in the myocardium may play a role in the
pathogenesis of CHF subsequent to MI. Attenuation of these
changes in antioxidant activity with vasodilator (or antioxidant?)
therapy mitigates the process of heart failure.
(J Am Coll Cardiol 1997;29:856–61)
q1997 by the American College of Cardiology
Although the clinical syndrome of congestive heart failure
(CHF) has long been recognized, and significant advances have
been made in its management, the pathophysiology of this
syndrome remains poorly understood. Irrespective of etiology,
several biochemical processes, including the production and
utilization of high energy phosphates, excitation–contraction
coupling and calcium metabolism, have been reported (1,2) to
be defective in CHF. Whether any or all these changes are the
result of the CHF condition, or whether in fact these may be
causal, remains unknown. Recent data from experimental
studies (3,4) have suggested that CHF in rats subsequent to
myocardial infarction (MI), as well as in guinea pigs subjected
to chronic pressure overload, may be caused by a decrease in
myocardial endogenous antioxidants and an increase in oxida-
tive stress. The latter has been shown (5,6) to cause myocardial
cell damage and loss of contractile function in ex vivo studies.
Direct evidence in support of this hypothesis has been pro-
vided by in vivo studies (7) in which the transition from
myocardial hypertrophy to CHF was attenuated by vitamin E
therapy. Analysis of breath pentane in patients with coronary
artery disease has also provided evidence of increased lipid
peroxidation and thus oxidative stress in CHF (8). The occur-
rence of myocardial antioxidant deficit as well as increased
oxidative stress subsequent to MI may be intimately linked to
CHF.
Although the efficacy of vasodilators in the management of
hypertension and CHF in patients has been well documented,
their effects on myocardial endogenous antioxidants remain to
be studied. Both captopril and prazosin have been shown
(9–14) to improve hemodynamic function in CHF subsequent
to MI. Captopril (10), but not prazosin (15), has also been
shown to reduce mortality. Whether this improved prognosis
with vasodilator therapy is associated with the modulation of
antioxidant changes remains to be determined. The present
study was therefore designed to test the hypothesis that
improved hemodynamic function with afterload reduction in
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the treatment of CHF may also involve an improvement in
myocardial endogenous antioxidant status. Changes in myocar-
dial antioxidant activity, oxidative stress, hemodynamic vari-
ables and tissue weight were examined at 1, 4 and 16 weeks
postoperatively. Captopril and prazosin therapy was started at
4 weeks after operation, and the studies were repeated at 16
weeks.
Methods
Animal model and study groups. Male Sprague-Dawley
rats weighing (mean 6 SE) 150 6 10 g were maintained on
standard rat chow and water ad libitum unless otherwise
indicated. MI was produced by occlusion of the left anterior
descending coronary artery (16,17). The animals were anesthe-
tized with 2% isoflurane, and the skin was then incised along
the left sternal border. The third and fourth ribs were cut
proximal to the sternum, with the subsequent insertion of
retractors. The pericardial sac was perforated, and the heart
was exteriorized through the intercostal space. The left main
coronary artery was ligated ;1 to 2 mm from its origin with a
6-0 silk thread. After ligation, the heart was gently repositioned
in the chest. Excess air was drawn into a syringe, and the chest
was closed. Closure of the incision was accomplished by a
purse-string suture. The rats were maintained on a positive
pressure ventilation delivering 2% isoflurane mixed with oxy-
gen throughout the operation. The entire surgical procedure
was carried out under sterile conditions. Control animals were
similarly treated, except that the suture around the coronary
artery was not tied, and the thread was passed only through the
muscle.
There were five experimental groups, each with its own
age-matched sham control group as follows: group 1 5 1-week
after MI (PMI) and 1-week sham control; group 2 5 4-week
PMI and 4-week sham control; group 3 5 16-week PMI and
16-week sham control; group 4 5 16-week PMI and 16-week
sham control, both treated with captopril; group 5 5 16-week
PMI and 16-week sham control, both treated with prazosin. In
groups 4 and 5, captopril (2 g/liter in drinking water) or
prazosin (0.2 mg/kg body weight subcutaneously daily) treat-
ment, respectively, was started 4 weeks after the operation and
was continued up to 16 weeks. Animals were monitored daily
for general behavior and food and water intake.
Hemodynamic studies. Rats were anesthetized with so-
dium pentobarbital (50 mg/kg intraperitoneally). A miniature
pressure transducer catheter (Millar Micro-Tip, model PR
249) was inserted into the right carotid artery and then
advanced into the left ventricle. Left ventricular end-diastolic
(LVEDP) and left ventricular peak systolic (LVPSP) pressures
were recorded on a computer for an on-line analysis (Axotape
acquisition data program and Acqknowledge 3.0). After these
assessments, the rats were killed, and the heart and other
organs were removed for further studies.
Tissue weight determination. To obtain the wet/dry weight
ratio of the lungs and liver, these organs were removed and
freed from adhering tissues. In each case, the sample tissue was
weighed, chopped into smaller pieces and placed in the oven at
658C until a constant weight was obtained, which was usually
after ;24 h.
Biochemical assays. For the studies of antioxidants and
lipid peroxidation, only viable portion of the ventricles were
utilized, as follows: Superoxide dismutase. Superoxide dis-
mutase (SOD) activity in the hearts was determined by a
previously described method (18). Hearts were homogenized
(1:10) in 50 mmol/liter Tris-HCl, pH 8.20, containing 1 mmol/
liter diethylenetriamine pentaacetic acid. The homogenate was
centrifuged at 20,000g for 20 min. The supernatant was aspi-
rated and assayed for total SOD activity by following the
inhibition of pyrogallol auto-oxidation. Pyrogallol (24 mmol/
liter) was prepared in 10 mmol/liter HCl and kept at 48C
before use. Catalase, 30 mmol/liter stock solution was prepared
in an alkaline buffer (pH 9.0). Aliquots of supernatant (150 mg
protein) were added to Tris-HCl buffer containing 25 ml of
pyrogallol and 10 ml of catalase. Changes in absorbance at
420 nm were recorded at 1-min intervals for 5 min. SOD
activity was expressed as units per milligram protein derived
from an SOD standard curve of pyrogallol autoxidation ob-
tained in the presence of commercially available SOD.
Glutathione peroxidase. Glutathione peroxidase (GSHPx)
activity was determined in whole heart as previously described
(19). Hearts were homogenized (1:10) in 75 mmol/liter phos-
phate buffer (pH 7.0). Homogenate was centrifuged at 20,000g
for 25 min, and the supernatant was aspirated and assayed for
total cytosolic GSHPx activity. GSHPx activity was assayed in a
3-ml cuvette containing 2.0 ml of 75 mmol/liter phosphate
buffer (pH 7.0). The following solutions were then added: 50 ml
of 60 mmol/liter glutathione, 100 ml of glutathione reductase
solution (30 U/ml), 50 ml of 0.12 mol/liter NaN3, 100 ml of 15
mmol/liter Na2 EDTA, 100 ml of 3.0 mmol/liter nicotinamide
adenine dinucleotide phosphate, reduced (NADPH) and 100
ml of cytosolic fraction. The reaction was started by the
addition of 100 ml of 7.5 mmol/liter H2O2, and the conversion
of NADPH to nicotinamide adenine dinucleotide phosphate
(NADP) was monitored by continuous recording of the change
in absorbance at 340 nm at 1-min intervals for 5 min. GSHPx
activity was expressed as nanomoles of reduced NADPH
oxidized to NADP per minute per milligram protein, with a
molar extinction coefficient for NADPH at 340 nm of 6.22 3
106.
Abbreviations and Acronyms
CHF 5 congestive heart failure
GSHPx 5 glutathione peroxidase
LVEDP 5 left ventricular end-diastolic pressure
LVPSP 5 left ventricular peak systolic pressure
MI 5 myocardial infarction
NADP 5 nicotinamide adenine dinucleotide phosphate
NADPH 5 nicotinamide adenine dinucleotide phosphate, reduced
PMI 5 post–myocardial infarction
SOD 5 superoxide dismutase
TBARS 5 thiobarbituric acid-reactive substances
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Catalase. Catalase activity in the hearts was determined as
previously described (20). Hearts were homogenized in (1:10)
50 mmol/liter potassium phosphate buffer (pH 7.4). Homoge-
nate was centrifuged at 40,000g for 30 min. Fifty microliters of
supernatant was added to a 3-ml cuvette that contained 2.95 ml
of 19 mmol/liter hydrogen peroxide in 50 mmol/liter potassium
phosphate buffer (pH 7.4). Changes in absorbance at 240 nm
were continuously monitored for 5 min. Catalase activity was
expressed as units per milligram protein.
Thiobarbituric acid reactive substances. Lipid peroxide con-
tent in hearts was determined by measuring the thiobarbituric
acid reactive substances (TBARS) as previously described
(21). Hearts were homogenized in (10% wt/vol) 0.2 mol/liter
Tris, 0.16 mol/liter KCl buffer (pH 7.4) and incubated at 378C
for 1 h. After 1 h, a 2-ml aliquot was collected from the
incubation mixture and poured into a Corning culture tube. To
this tube, 2.0 ml of 40% trichloroacetic acid and 1.0 ml of 0.2%
thiobarbituric acid (TBA) were added; 100 ml of 2% butylated
hydroxy toluene was added to the thiobarbituric reagent
mixture to minimize peroxidation during the assay procedure.
The mixture was then boiled for 15 min and allowed to cool on
ice for 5 min; 2 ml of 70% trichloroacetic acid was then added,
and the tubes were allowed to stand for 20 min. After 2 min,
the sample was centrifuged at 800g for 20 min. The developed
color was read at 532 nm. Commercially available malondial-
dehyde was used as the standard.
Proteins and statistical analysis. Proteins were deter-
mined by the method described by Lowry et al. (22). Results
are expressed as mean value 6 SEM. For statistical analysis of
the data, group means were compared by one-way analysis of
variance and a Bonferroni test. A value of p , 0.05 were
considered significant.
Results
General characteristics and mortality. No unusual changes
in general appearance or behavior were observed in any of the
sham control or the 1- and 4-week PMI groups. In the 16-week
untreated PMI group, rats showed clear signs of dyspnea. The
mortality rate in the coronary ligated animals during or
immediately after the operation was 20%. Another 12% of the
rats died within 24 h of the operation. There was no difference
between control and experimental rats with respect to food and
water intake at 1, 4 and 16 weeks.
Lung and liver wet/dry weight ratios. There was no change
in lung and liver wet/dry weight ratios in the PMI groups at 1
and 4 weeks (Table 1). However, at 16 weeks in the PMI
groups, the ratios for the liver and lungs were ;25% and 33%
higher, respectively, than those in the 16-week sham control
group, and these differences were statistically significant. In the
16-week treated PMI group, captopril and prazosin treatment
significantly attenuated the wet/dry weight ratios for both the
lungs and the liver. Neither drug had any effect on these ratios
in the sham control rats (Table 1).
Hemodynamic variables. In the untreated PMI groups,
LVPSP was unchanged at 1 week, marginally reduced at 4
weeks and significantly depressed at 16 weeks (Table 2);
LVEDP was unchanged at 1 week but was significantly ele-
vated at 4 and 16 weeks (Table 2). In the 16-week treated PMI
groups, both captopril and prazosin attenuated the increase in
LVEDP, and LVPSP was significantly higher than that in the
untreated 16-week PMI group (Table 2).
Antioxidant enzymes. SOD activity remained unchanged in
the 1-week PMI and sham control groups (Table 3) but
decreased ;19% and 45% in the 4- and untreated 16-week
PMI groups, respectively, compared with their respective sham
control groups, and these changes were statistically significant.
GSHPx activity was marginally higher in the 1-week PMI group
relative to sham control values, but the change was not
significant (Table 3). However, in the 4-week and untreated
16-week PMI groups, GSHPx activity was depressed by 30%
and 37%, respectively, relative to sham control values. A
similar trend was seen with respect to catalase activity (Table
3): There was no change in catalase activity in the 1-week PMI
group but a significant decrease in the 4-week and 16-week
untreated PMI groups of ;27% and ;40%, respectively.
Captopril or prazosin therapy resulted in an improvement
in SOD activity in the treated versus the untreated 16-week
Table 1. Lung and Liver Wet/Dry Weight Ratios in Sham and Infarcted Rats at 1, 4 and 16 Weeks
After Operation and Effect of Afterload Reduction Therapy at 16 Weeks
Postoperative
Period
Lung Liver
Sham Control Group PMI Group Sham Control Group PMI Group
No therapy
1 wk 4.76 6 0.19 4.78 6 0.22 3.19 6 0.02 3.20 6 0.51
4 wk 4.66 6 0.27 4.97 6 0.58 3.21 6 0.54 3.42 6 0.11
16 wk 4.64 6 0.19 6.20 6 0.32* 3.22 6 0.17 4.04 6 0.28†
Therapy‡
Captopril (16 wk) 4.21 6 0.27 4.71 6 0.17§ 3.47 6 0.3 2.91 6 0.5§
Prazosin (16 wk) 4.28 6 0.39 4.43 6 0.57§ 2.95 6 0.46 3.12 6 0.1§
*p , 0.05 versus sham control group by analysis of variance (ANOVA) followed by Bonferroni test. †p , 0.05 versus
sham control group by ANOVA. ‡Captopril or prazosin therapy was started at 4 weeks and continued up to 16 weeks,
as described in Methods. §p , 0.05 versus 16-week untreated post–myocardial infarction (PMI) group by ANOVA. Data
presented are mean value 6 SE of five to eight experiments.
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PMI group (Table 3). GSHPx activity in captopril-treated
16-week PMI group was higher than that in the untreated
16-week PMI group but remained unchanged in the prazosin-
treated group compared with the untreated 16-week PMI
group. Catalase activity was significantly higher in the
captopril-treated 16-week PMI group that in the untreated
16-week PMI group and showed some increase in the prazosin-
treated 16-week PMI group over that in the untreated 16-week
PMI group, but the change was not statistically significant.
Lipid peroxidation. Lipid peroxidation was assessed in the
1-, 4- and 16-week sham and PMI groups by evaluating
myocardial TBARS (Table 3). TBARS in the 1-week PMI
group remained unchanged relative to its respective sham
control group but increased by 12% and 48%, respectively, in
the 4-week and untreated 16-week PMI groups relative to their
respective sham control groups. The increase in the untreated
16-week PMI group was statistically significant.
TBARS in the 16-week sham control groups treated with
captopril or prazosin remained unchanged relative to the
16-week untreated PMI group (Table 3). However, TBARS
was significantly lower in the captopril- and prazosin-treated
16-week PMI groups than the untreated 16-week PMI group.
Discussion
To our knowledge, the present study demonstrates for the
first time that improved hemodynamic function subsequent to
afterload reduction therapy in rats after MI is associated with
an increase in antioxidant levels and a decrease in oxidative
stress in the heart. The study supports the hypothesis that
antioxidant deficit may have a role in the pathogenesis of CHF
subsequent to MI.
Progressive CHF subsequent to MI. In untreated rats at 1
week PMI, there was no change in LVPSP and LVEDP. Signs
of lung and liver congestion were also not apparent, indicating
1 week PMI to be a “nonfailure” stage. However, at 4 weeks
Table 2. Left Ventricular Pressure in Sham and Infarcted Rats at 1, 4 and 16 Weeks After Operation
and Effect of Afterload Reduction Therapy at 16 Weeks
Postoperative
Period
LVEDP (mm Hg) LVPSP (mm Hg)
Sham Control Group PMI Group Sham Control Group PMI Group
No therapy
1 wk 2.0 6 0.28 2.2 6 1.4 125.7 6 6.7 130.7 6 5.9
4 wk 2.6 6 0.63 6.5 6 0.9† 124.5 6 8.3 109.5 6 1.7
16 wk 3.3 6 0.60 27.5 6 1.2* 128.7 6 4.6 88.6 6 2.8*
Therapy‡
Captopril (16 wk) 3.2 6 0.4 10.8 6 0.2†§ 129.3 6 6.2 103.2 6 4.7†§
Prazosin (16 wk) 2.8 6 0.5 8.2 6 1.6†§ 125.2 6 6.2 115.6 6 4.6§
*p , 0.05 versus sham control group by analysis of variance (ANOVA) followed by Bonferroni test. †p , 0.05 versus
sham control group by ANOVA. ‡Captopril or prazosin therapy was started at 4 weeks and continued up to 16 weeks,
as described in Methods. §p , 0.05 versus 16-week post–myocardial infarction (PMI) group by ANOVA. Data presented
are mean value 6 SE for six to eight rats. LVEDP 5 left ventricular end-diastolic pressure; LVPSP 5 left ventricular
peak systolic pressure.
Table 3. Antioxidant Enzyme Activity and Lipid Peroxidation in Sham and Infarcted Rats at 1, 4 and 16 Weeks After Operation and Effect of
Afterload Reduction Therapy at 16 Weeks
Postoperative Period
Antioxidant Enzyme Activity
Lipid Peroxidation
(TBARS [nmol/g wet wt])SOD (U/mg protein)
GSHPx
(nmol/mg protein) Catalase (U/mg protein)
Sham Control
Group
PMI
Group
Sham Control
Group
PMI
Group
Sham Control
Group
PMI
Group
Sham Control
Group
PMI
Group
No Therapy
1 wk 35.2 6 3.1 38.1 6 2.7 86.4 6 1.9 96.6 6 6.9 26.9 6 1.7 29.4 6 2.8 74.7 6 5.3 72.1 6 0.8
4 wk 34.8 6 5.1 28.2 6 4.2* 84.6 6 1.6 60.3 6 1.9* 30.8 6 2.6 22.3 6 1.7* 70.2 6 2.9 78.1 6 4.5
16 wk 33.1 6 5.3 18.1 6 4.7† 78.6 6 2.8 49.5 6 3.6† 29.7 6 2.3 18.4 6 3.5* 71.1 6 3.1 104 6 7.5*
Therapy
Captopril (16 wk) 35.1 6 2.7 24.2 6 10.5‡ 76.1 6 6.7 69.2 6 0.5§ 32.3 6 3.8 38.5 6 2.5§ 72.1 6 2.7 80 6 2.8§
Prazosin (16 wk) 35.2 6 10.1 29.2 6 7.6‡ 82.9 6 2.5 46.3 6 4.7* 29.1 6 1.9 22.4 6 1.7* 71.4 6 1.4 89.6 6 2.4§
*p , 0.05 versus sham control group by analysis of variance (ANOVA). †p , 0.05 versus sham control group by ANOVA followed by Bonferroni test; captopril
or prazosin therapy was started at 4 weeks and continued up to 16 weeks, as described in Methods. ‡p , 0.05 versus the 16-week untreated post–myocardial infarction
(PMI) group by ANOVA. Data presented are mean value 6 SE for six to eight rats. GSHPx 5 glutathione peroxidase; SOD 5 superoxide dismutase; TBARS 5
thiobarbituric acid reactive substances.
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PMI, LVEDP was significantly elevated, whereas LVPSP was
slightly depressed, but the change was not significant. Pulmo-
nary edema and liver congestion were also absent in this
experimental group. Thus, 4 weeks PMI was considered to be
a “mild failure” and functionally compensated stage. At 16
weeks PMI, LVEDP increased along with a significant depres-
sion in LVPSP. Lung and liver wet/dry weight ratios were
significantly higher. All these features, along with respiratory
distress, in these animals suggested 16 weeks PMI be in a
“severe failure” stage. The increase in LVEDP and congestion
of lung and liver seen in our study at 16 weeks have also been
previously reported by several other studies using this animal
model (3,9,17). Heart failure appears to worsen with duration
of the postoperative period.
Afterload reduction and attenuation of heart failure. Be-
cause the early signs of CHF were evident at 4 weeks, vaso-
dilatory therapy was started at this stage. Data for the
captopril- and prazosin-treated groups demonstrated not only
improved hemodynamic function at 16 weeks PMI but also the
absence of any signs of respiratory distress as well as lung and
liver congestion. Normalization of hemodynamic variables in
the infarcted rats after prolonged treatment with captopril has
been reported (9). In the SAVE trial (23) in humans with left
ventricular dysfunction, captopril was reported to improve
survival and reduce morbidity and mortality. In another study
in patients with symptomless left ventricular dysfunction after
MI (24), treatment with captopril attenuated ventricular en-
largement and prevented further deterioration of ventricular
performance. In a canine model of MI, treatment with capto-
pril, enalapril and isosorbide dinitrate improved left ventricu-
lar geometry and function after both anterior and inferior
infarctions (25,26). In contrast, prazosin has been shown
(12–15) to improve morbidity but not mortality. In a long-term
follow-up study (13), prazosin was found to improve New York
Heart Association functional class (3.7 to 2.2, p , 0.001) and
to be effective in the ambulatory management of CHF. Thus,
previous studies have clearly demonstrated the beneficial
effects of both drugs in patients as well as in experimental
models. However, the subcellular mechanisms for improve-
ment at the myocardial level have not been precisely defined.
In this regard, loss of myocytes (27) as well as subcellular
abnormalities in individual myocytes may play an important
role.
Antioxidant deficit and heart failure. Findings of the
present study as well as other published data (3,7,8) suggest
that the improved “antioxidant reserve” (28,29) may form an
important part of the attenuation of subcellular changes
leading to CHF. In our model of CHF, characteristic changes
in SOD, GSHPx and catalase activity were seen at different
time points after MI. Antioxidant activity showed either no
change or a slight trend toward an increase at 1 week after MI;
a significant depression at 4 weeks after MI; and an even
greater reduction at 16 weeks after MI. Antioxidant decrease
in CHF subsequent to MI has been previously documented (3).
In the present study, the presence of depressed antioxidant
reserves or increased oxidative stress at 16 weeks was also
suggested by an increase in lipid peroxidation. Increased lipid
peroxidation has been reported in experimental models of
CHF, such as CHF due to pressure overload in guinea pigs (4),
subsequent to MI in rats (3) and in cardiomyopathic hamsters
(30). An increase in lipid peroxidation, measured by breath
pentane content, is also known to occur in patients with CHF
(8,31). Thus, the present study suggests that poor cardiac
function or CHF may in fact be linked to the decrease in
antioxidant activity and an increase in lipid peroxidation.
Improved antioxidant reserves and attenuation of heart
failure. The present study also showed that long-term treat-
ment with captopril not only improved hemodynamic function,
but also resulted in better maintenance of antioxidant enzyme
activity. As a result, oxidative stress in the captopril-treated
16-week PMI group was significantly less than that in the
untreated 16-week PMI group, as was evidenced by a decrease
in myocardial lipid peroxidation in the drug-treated groups.
Thus, our data as well as the findings reported by others
suggest that a relative deficit in antioxidant activity and an
increase in oxidative stress may play an important role in the
pathogenesis of CHF (28,29,32). Because of the other humoral
and tissue level effects of angiotensin-converting enzyme and
angiotensin II, the exact mechanism by which angiotensin-
converting enzyme inhibition with captopril treatment im-
proves left ventricular function is not yet defined. In this
regard, sulfydryl groups in captopril may act as free radical
scavengers (8,33), and some component of protection may also
result from a direct antioxidant effect of the drug. Vasodilatory
effects of captopril through mechanisms other than modifying
angiotensin II levels have also been reported (34). Captopril
has been shown to increase the activity of bradykinin, a potent
vasodilator (34), and to stimulate the production and release of
prostacyclin (35). However, prazosin, another vasodilator with
no known antioxidant property, significantly improved cardiac
function and alleviated signs of CHF. Prazosin reduced myo-
cardial lipid peroxidation as measured by TBARS and also
improved levels of SOD. There is also a clinical evidence of
reduced pulmonary venous congestion and enhanced exercise
tolerance with prazosin (13,15,36,37).
Conclusions. To our knowledge, our study demonstrated
for the first time that an afterload reduction was not only
accompanied by an improvement in hemodynamic variables,
but also by an increase in antioxidant activity and a decrease in
oxidative stress. Because protection was seen with both vaso-
dilators (captopril and prazosin), it is likely that the primary
beneficial effect may be due to afterload reduction or a
reduction in myocardial wall stress, which may then influence
antioxidant activity and oxidative stress through a yet unde-
fined mechanism. Afterload reduction is clearly beneficial in
the treatment of CHF, and attenuation of antioxidant activity
as well as oxidative stress changes that occur during CHF may
play a role in this beneficial effect. An understanding of the
molecular basis of the antioxidant changes subsequent to after-
load reduction may lead to the use of an early and targeted gene
therapy that can play an important role in preventing CHF.
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